Delix Therapeutics的动态

Precision medicine innovation and the role of ecosystems This whitepaper, Fuelling the future: Precision medicine innovation and the role of ecosystems, examines how the future of drug discovery and precision medicine can be enhanced by life science ecosystems such as those created by the UK's leading property developer to the science and technology sectors, Bruntwood SciTech. In the whitepaper, you will discover: - The evolution of precision diagnostics for oncology in the North West of England - How life science ecosystems enable key breakthroughs in precision medicine - A view into the future of precision medicine developments. Download Whitepaper https://lnkd.in/eKYQ5d-M Brought to you by Bruntwood SciTech #PrecisionMedicine #DrugDiscovery #Diagnostics

APIS has been featured in the Bruntwood SciTech and Drug Discovery World whitepaper: 'Fuelling the future: Precision medicine innovation and the role of ecosystems' Check it out below!

Pharmidex at the 2nd Swiss Translational Medicine Conference! Ash Alavijeh, our Head of Operations, is attending the 2nd Swiss Translational Medicine Conference in Bern! If you're attending, we’d love for you to stop by the Pharmidex stand and say hello! Ash will be more than happy to chat with you about our cutting-edge preclinical services and how we can support your translational research needs. Looking forward to seeing you there! #STMC2024 #Pharmidex #TranslationalMedicine #PreclinicalServices

We congratulate Md SamimSardar, Kardile Punam, Ujjwal Gupta, Dr Subhadeep Roy, and Santanu Kaity for publishing a review article entitled "Polymeric nanotheranostics for solid tumor management: Recent developments and global regulatory Landscape" in the journal "Polymers for Advanced Technologies" by Wiley. This comprehensive review delves into the advancements in polymeric nanotheranostics, highlighting their potential to revolutionize the management of solid tumors. We explore cutting-edge developments, innovative technologies, and the evolving global regulatory landscape that shapes this dynamic field. DOI: ?https://lnkd.in/g4P6NcUY #Nanotechnology #CancerResearch #Theranostics #PolymericNanoparticles #ScientificResearch #HealthcareInnovation

The Flinn Foundation released its latest report on Greater Phoenix’s #bioscience assets which identifies three growth areas including precision oncology, digital health tech, and translational neuroscience. Biotechnology, health and life sciences is one of Gilbert, Arizona’s strongest business segments. The cluster’s growth over the last five years (49%) was almost double that of the state and is projected to grow by another 16% in the next five years. #Biotech #marketopportunities #greaterPHXtogether ?? For the full report, click here:?https://lnkd.in/gttfgBXX

???????????????????? ???????????????? ???? ?????????????????? ???????????? ?????????????? ????????????????????????? ???? Link in the first comment! ?? How can ???????????????????????? help restore vision in cases of retinal degeneration? Qi Lu, Anna Wright & Pan Zhuo-Hua, from Wayne State University, studied the effects of AAV dose on retinal ganglion cells (RGCs) and efficacy of optogenetic vision restoration. This preclinical study, published in ???????? ??????????????, provides important insights into potential therapies to restore vision in patients affected by blindness. We’re proud that Striatech’s ???????????????? ????????????? played a role in this cutting-edge research, enabling precise measurements of visual function after restoring vision. ?? Curious to learn more? Read our latest blog article to explore the study and its implications for optogenetic vision restoration. #Optogenetics #VisionRestoration #GeneTherapy #Striatech #InnovationInResearch

?? NTx's CEO Dominik Witzigmann, PhD takes the stage at the Biophysics Forum in Drug Delivery ?? ? We're proud to share that Dom, our visionary CEO, will be an esteemed speaker at the Biophysics Forum in Drug Delivery, held in #Copenhagen on 27-28 May. Dom will address "Rigorous characterization as a key factor for developing the next-generation of LNP technologies" — a topic at the heart of NanoVation Therapeutics' pioneering work. ? ???His talk will highlight our dedication to the rational design of lipid nanoparticles. How can we learn from the past? How can we leverage our fundamental understanding of lipid biophysics? Pushing the boundaries of nucleic acid delivery to revolutionize medicine. Meet other key opinion leaders like: Camilla Foged, U of Copenhagen Eric Ennifar, CNRS Marianna Yanez Arteta, AstraZeneca Niels Delamotte, ETherna NTx biophysics expert Hanna Barriga, Karolinska institute And others prominent experts! Thanks Natalia Markova (Malvern Panalytical) for putting together an excellent event:?https://lnkd.in/deUxeK7p ? #BiophysicsForum #DrugDelivery #GeneticMedicine #NucleicAcids #LipidNanoparticles??#genetherapy #RNA

Neurotechnology Investors (NTI) is proud to highlight the progress of portfolio company FreeOx Biotech, which has achieved a significant step forward in its clinical development program. The company’s lead compound, Ox-01, has been selected by the National Institute of Neurological Disorders and Stroke (NINDS) for inclusion in the StrokeNet Thrombectomy Endovascular Platform (STEP) clinical program. This selection follows a rigorous evaluation through NINDS’ SPAN (Stroke Preclinical Assessment Network) and positions FreeOx to advance toward its Phase 2/3 AURORA trial in 2025. As an adjunctive treatment for Acute Ischemic Stroke (AIS), Ox-01 represents the type of innovative approach that aligns with NTI’s mission to support transformative solutions addressing critical unmet needs. We congratulate the FreeOx team on this milestone and look forward to their continued progress. ? #Stroke #StrokeResearch #FreeOxBiotech #Innovation

? Our 10th Annual Conference will be held on October 24th in Basel, Switzerland, and we are now announcing our first lineup of speakers! Discover them and their intriguing topics. Join us in person or online—learn more and register here ?? https://lnkd.in/dScYhW4U ?? As we look forward to this year’s conference, we can also revisit last year’s event. We wrote an article titled “Closing the Gap: The Benefits of Animal-Free 3D Models,” which provides insight into still highly relevant topics. Explore the subjects covered last year: 1. Limitations of animal models in preclinical drug discovery 2. Bridging the translational gap with 3D cell culture: The value of organoid models across drug discovery, Live cell imaging and isolation of organoids, Patient-derived organoids, and personalized medicine 3. Animal-derived versus animal-free 3D culture products in drug discovery: Compatibility with automation technologies, Liver organoids and microphysiological systems 4. Turning the tide against clinical failures ?? Read the whole article here: https://lnkd.in/dEzPcjNG

Taconic scientist Mayara Grizotte-Lake, PhD discusses the preclinical applications of the hIL-2 NOG mouse. This super immunodeficient humanized murine tool is especially useful in #psoriasis research as it more accurately models dysregulation of the immune system, leading to more translatable findings. Learn more here: https://hubs.li/Q02T7lxZ0